TFF Pharmaceuticals, Inc. (0K3.F)
| Previous Close | 0.8300 |
| Open | 0.8250 |
| Bid | 0.8400 x N/A |
| Ask | 0.8700 x N/A |
| Day's Range | 0.8250 - 0.8250 |
| 52 Week Range | 0.7550 - 6.5000 |
| Volume | |
| Avg. Volume | 11 |
| Market Cap | 20.932M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7540 |
| Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- GlobeNewswire
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Dr. Mikhak will be responsible for the clinical development of the Company’s pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled
- GlobeNewswire
TFF Pharmaceuticals Announces Leadership Transition
Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will ste
- GlobeNewswire
TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering
Underwriters Exercise Their Option in FullFORT WORTH, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced underwritten offering of 10,675,001 shares of its common stock and warrants to purchase up to 5,337,501 shares of common stock. T
